Urology Research & Practice
UROONCOLOGY - Original Article
The expression of matrix-metalloproteinase-2 in bone marrow micro-metastasis is associated with the presence of circulating prostate cells and a worse prognosis in men treated with radical prostatectomy for prostate cancer

The expression of matrix-metalloproteinase-2 in bone marrow micro-metastasis is associated with the presence of circulating prostate cells and a worse prognosis in men treated with radical prostatectomy for prostate cancer

1.

University Finis Terrae, Faculty of Medicine, Santiago, Chile

2.

Urology Service, Hospital DIPRECA; University Diego Portales, Faculty of Medicine, Santiago, Chile

3.

Urology Service, Hospital DIPRECA, Santiago, Chile

4.

University Mayor, Faculty of Medicine, Santiago, Chile

Urol Res Pract 2020; 46: 186-195
DOI: 10.5152/tud.2020.19219
Read: 1295 Downloads: 509 Published: 11 March 2020

Objective: The expression of matrix-metalloproteinase-2 (MMP-2) in the primary tumor is associated with a worse prognosis but little is known at this time regarding the expression in micro-metastasis, the association with circulating prostate cells (CPCs), and outcome.

Material and methods: This was a prospective study of men undergoing radical prostatectomy. Bone marrow and blood samples were taken at one month after surgery. Micro-metastasis and CPCs were identified using immunocytochemistry with anti-prostate specific–antigen and MMP-2 expression determined with anti–MMP-2. Pathological stage, Gleason score, and time to biochemical failure were recorded; meanwhile, Kaplan–Meier biochemical failure–free survival and restricted mean biochemical failure–free survival times for 10 years were determined.

Results: A total of 282 men participated, 54 (19%) of whom had micro-metastasis but not CPCs (group B) and 88 (31%) of whom had micro-metastasis and CPCs (group C). Men in group C had a higher frequency of MMP-2 expressing micro-metastasis at 63% versus 12% (p<0.001), and MMP-2 expression in bone marrow micro-metastasis was associated with a higher Gleason score (p<0.05) as well as a higher frequency of and shorter time to treatment failure. Also, a 10-year Kaplan–Meier biochemical failure–free survival rate of 0% versus 7.7% (MMP-2 positive versus negative) and a mean time to biochemical failure of 2.6 versus 4.0 years were recorded.

Conclusion: The expression of MMP-2 in bone marrow micro-metastasis is associated with a higher Gleason score, the presence of CPCs, and a higher frequency of and shorter time to failure and could be clinically useful for identifying men at high risk of treatment failure.

Cite this article as: Murray NP, Reyes E, Salazar A, Lopez MA, Orrego S, Guzman E. The expression of matrix-metalloproteinase-2 in bone marrow micro-metastasis is associated with the presence of circulating prostate cells and a worse prognosis in men treated with radical prostatectomy for prostate cancer. Turk J Urol 2020; 46(3): 186-95.

Files
EISSN 2980-1478